| scholarly article | Q13442814 |
| P2093 | author name string | S A Rosenberg | |
| C J Kim | |||
| N P Restifo | |||
| M Roden | |||
| F M Marincola | |||
| J Cormier | |||
| T Prevette | |||
| W Overwijk | |||
| P2860 | cites work | Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor | Q24312048 |
| A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma | Q24319940 | ||
| Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products | Q24678867 | ||
| Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution | Q24679240 | ||
| Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTL | Q24684276 | ||
| Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha | Q28251443 | ||
| Presentation of viral antigen controlled by a gene in the major histocompatibility complex | Q28285937 | ||
| The dendritic cell system and its role in immunogenicity | Q29619870 | ||
| Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity | Q71563753 | ||
| Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides | Q71614134 | ||
| Contribution of proteasome-mediated proteolysis to the hierarchy of epitopes presented by major histocompatibility complex class I molecules | Q71684049 | ||
| Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cells | Q71699059 | ||
| Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides | Q71804817 | ||
| Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro | Q71805057 | ||
| Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression | Q72133139 | ||
| Peptide and protein antigens require distinct antigen-presenting cell subsets for the priming of CD4+ T cells | Q72191639 | ||
| Role of dendritic cells in the priming of CD4+ T lymphocytes to peptide antigen in vivo | Q72660264 | ||
| TNF and GM-CSF dependent growth of an early progenitor of dendritic Langerhans cells in human bone marrow | Q72938515 | ||
| Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans | Q34195888 | ||
| Influenza virus-infected dendritic cells stimulate strong proliferative and cytolytic responses from human CD8+ T cells | Q34229490 | ||
| Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens | Q34291693 | ||
| HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides | Q34372218 | ||
| Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen | Q35945206 | ||
| Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen | Q35990356 | ||
| IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases | Q36091993 | ||
| Identification of an autologous insulin B chain peptide as a target antigen for H-2Kb-restricted cytotoxic T lymphocytes | Q36230926 | ||
| Detection of shared MHC-restricted human melanoma antigens after vaccinia virus-mediated transduction of genes coding for HLA | Q36238343 | ||
| Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ | Q36352646 | ||
| Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes | Q36363449 | ||
| Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes | Q36364266 | ||
| Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes | Q36365159 | ||
| Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity | Q36366051 | ||
| Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines | Q36366108 | ||
| Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo | Q36366124 | ||
| Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity | Q36366130 | ||
| Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35) | Q36367223 | ||
| Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses | Q36470715 | ||
| Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes | Q36470734 | ||
| A new microcellular cytotoxicity test based on calcein AM release | Q36761954 | ||
| Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A | Q37003339 | ||
| Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes | Q38310540 | ||
| Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy? | Q40507181 | ||
| Dendritic cell activity against primary tumors: an overview. | Q40838699 | ||
| Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions. | Q41200467 | ||
| Human dendritic Langerhans cells generated in vitro from CD34+ progenitors can prime naive CD4+ T cells and process soluble antigen. | Q41266804 | ||
| Genetic polymorphism within HLA-A*02: significant allelic variation revealed in different populations. | Q41355200 | ||
| Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. | Q41363142 | ||
| Loss of HLA haplotype and B locus down-regulation in melanoma cell lines | Q41451344 | ||
| A nonimmunodominant nucleoprotein-derived peptide is presented by influenza A virus-infected H-2b cells | Q41467928 | ||
| Recombinant anticancer vaccines | Q41483699 | ||
| In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. | Q41529681 | ||
| Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells | Q41532466 | ||
| Peptide binding to class I MHC on living cells and quantitation of complexes required for CTL lysis | Q41675478 | ||
| Limit of T cell tolerance to self proteins by peptide presentation | Q41739980 | ||
| Immunomodulation during prolonged treatment with combined interleukin-2 and interferon-alpha in patients with advanced malignancy | Q41827234 | ||
| Identification of a novel cell type in peripheral lymphoid organs of mice. 3. Functional properties in vivo | Q42837010 | ||
| Characterization of dual-reactive H-2Kb-restricted anti-vesicular stomatitus virus and alloreactive cytotoxic T cells | Q45834793 | ||
| Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells | Q46578425 | ||
| GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells | Q59067424 | ||
| Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability | Q71049397 | ||
| Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy | Q71059459 | ||
| Duration of TCR stimulation determines costimulatory requirement of T cells | Q71400856 | ||
| Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A/MART-1 self antigen | Q71420846 | ||
| Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues | Q71527769 | ||
| P433 | issue | 4 | |
| P921 | main subject | dendritic cell | Q506253 |
| P304 | page(s) | 276-286 | |
| P577 | publication date | 1997-07-01 | |
| P1433 | published in | Journal of Immunotherapy | Q15763946 |
| P1476 | title | Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro | |
| P478 | volume | 20 |
| Q41481423 | A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes |
| Q35747229 | An effective cancer vaccine modality: lentiviral modification of dendritic cells expressing multiple cancer-specific antigens |
| Q36509697 | Biased epitope selection by recombinant vaccinia-virus (rVV)-infected mature or immature dendritic cells |
| Q34452007 | Biological and clinical developments in melanoma vaccines |
| Q74639680 | Cancer gene therapy |
| Q33586656 | Cancer vaccines: novel approaches and new promise |
| Q34280913 | Dendritic cells for specific cancer immunotherapy |
| Q45722523 | Dendritic cells infected with a vaccinia virus interleukin-2 vector secrete high levels of IL-2 and can become efficient antigen presenting cells that secrete high levels of the immunostimulatory cytokine IL-12. |
| Q32067271 | Differential processing of class-I-restricted epitopes by the standard proteasome and the immunoproteasome |
| Q43983069 | Efficient generation of cytotoxic T lymphocytes against cervical cancer cells by adeno-associated virus/human papillomavirus type 16 E7 antigen gene transduction into dendritic cells |
| Q73462113 | Extensive characterization of dendritic cells generated in serum-free conditions: regulation of soluble antigen uptake, apoptotic tumor cell phagocytosis, chemotaxis and T cell activation during maturation in vitro |
| Q34267674 | Gene therapy of metastatic disease: progress and prospects. |
| Q81308391 | Immune characterization of clinical grade-dendritic cells generated from cancer patients and genetically modified by an ALVAC vector carrying MAGE minigenes |
| Q34267670 | Immunotherapy of metastasis. |
| Q35027788 | Introduction to cancer gene therapy |
| Q35875302 | Mechanisms of tumor evasion from the immune response. |
| Q45734168 | Rapid induction of cytotoxic T-cell response against cervical cancer cells by human papillomavirus type 16 E6 antigen gene delivery into human dendritic cells by an adeno-associated virus vector |
| Q33957705 | Strategies for immunotherapy of cancer |
| Q37266210 | Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. |
| Q34452071 | T-cell-directed cancer vaccines: the melanoma model |
| Q73009798 | The dendritic cell and human cancer vaccines |
| Q36916492 | Transfectant influenza A viruses are effective recombinant immunogens in the treatment of experimental cancer |
| Q39814228 | Tumor cell lysate-pulsed dendritic cells induce a T cell response against colon cancer in vitro and in vivo |
| Q40487777 | Use and specificity of breast cancer antigen/milk protein BA46 for generating anti-self-cytotoxic T lymphocytes by recombinant adeno-associated virus-based gene loading of dendritic cells |
| Q36691357 | Whole tumor antigen vaccination using dendritic cells: comparison of RNA electroporation and pulsing with UV-irradiated tumor cells. |
| Q35058235 | Whole tumor antigen vaccines |
Search more.